CD3(-)CD56(+) non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance
CD3(-)CD56(+) non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance
复制标题
DOI：
10.1182/blood.v89.8.2966
复制
发表时间：
1997-04-15
期刊：
影响因子：
20.3
通讯作者：
Fauchet, R
中科院分区：
文献类型：
--
作者：
Drenou, B;Lamy, T;Fauchet, R
CD56 表达先前已在一些非霍奇金淋巴瘤 (NHL) 特征中报道过。它们主要涉及鼻咽，与 Epstein-Barr 病毒 (EBV) 有关，根据基因组或蛋白质水平的 CD3/T 细胞受体 (TCR) 状态可分为 T 或非 T 自然杀伤 (NK) 细胞。本研究报告了三例非鼻 NK-NHL 病例，具有以下特征：攻击性临床行为、异质形态数据诱发多形性 T 细胞恶性淋巴瘤、使用流式细胞术检测的非 T-NK 表型和免疫化学。 3例均为CD56(+)，无特异性T标志物(CD3、CD5和TCR)的膜表达，不同抗原观察到异质结果：CD2、CD4、CD8、CD16、CD94、CD122、TiAl、穿孔素和颗粒酶B。聚合酶链反应没有可检测到克隆性TCR基因重排的证据。两例检测病例均未检测到NK活性，未发现与EBV相关。多药耐药性研究表明，侵袭性临床结果可能与 MDR1 基因表达有关，MDR1 mRNA 检测、MDR1 基因产物 (Pgp) 表达以及通过流式细胞术使用罗丹明流出的功能性多药耐药性研究证实了这一点。 (C) 1997 年，美国血液学会。
CD56 expression has been reported previously in some non-Hodgkin's lymphoma (NHL) characterization. They principally involve the nascapharynx, are related to Epstein-Barr virus (EBV), and may be classified as either T- or non-T-natural killer (NK) cells according to CD3/T-cell receptor (TCR) status at the genomic or protein level. The present study reports three cases of non-nasal NK-NHL with the following characteristics: an agressive clinical behavior, heterogenous morphological data evoking pleomorphic T-cell malignant lymphoma, a non-T-NK phenotype using flow cytometry, and immunochemistry. The three cases were CD56(+) without membrane expression of specific T markers (CD3, CD5, and TCR), Heterogenous results were observed concerning different antigens: CD2, CD4, CD8, CD16, CD94, CD122, TiAl, perforin, and granzyme B. There was no evidence of detectable clonal TCR gene rearrangement with polymerase chain reaction. No NK activity was detected in the two tested cases, and no relation was found with EBV. Multidrug resistance investigations suggest that agressive clinical findings could be related to MDR1 gene expression as confirmed by MDR1 mRNA detection, MDR1 gene product (Pgp) expression, and a functional multidrug resistance study using rhodamine efflux by flow-cytometry. (C) 1997 by The American Society of Hematology.